193 related articles for article (PubMed ID: 33189734)
1. Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH.
Guerrios-Rivera L; Howard LE; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Freedland SJ
Urology; 2021 Mar; 149():181-186. PubMed ID: 33189734
[TBL] [Abstract][Full Text] [Related]
2. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
3. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
5. Obesity, race, and long-term prostate cancer outcomes.
Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
[TBL] [Abstract][Full Text] [Related]
7. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
8. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
9. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
[TBL] [Abstract][Full Text] [Related]
10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
11. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
Cancer; 2007 Nov; 110(10):2202-9. PubMed ID: 17876838
[TBL] [Abstract][Full Text] [Related]
12. Is Hispanic race an independent risk factor for pathological stage in patients undergoing radical prostatectomy?
Lam JS; Desai M; Mansukhani MM; Benson MC; Goluboff ET
J Urol; 2003 Dec; 170(6 Pt 1):2288-91. PubMed ID: 14634398
[TBL] [Abstract][Full Text] [Related]
13. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
Deka R; Parsons JK; Simpson DR; Riviere P; Nalawade V; Vitzthum LK; Kader AK; Kane CJ; Rock CS; Murphy JD; Rose BS
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):581-588. PubMed ID: 32327702
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
15. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
18. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
19. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
20. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
